Menu
×
Baxter-Patrick James Island
9 a.m. - 8 p.m.
Phone: (843) 795-6679
West Ashley Library
9 a.m. - 7 p.m.
Phone: (843) 766-6635
Wando Mount Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 1 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. - 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. - 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. - 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. - 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. - 8 p.m.
Phone: (843) 766-2546
Folly Beach Library
Closed
Phone: (843) 588-2001
Edisto Island Library
2 p.m. – 6 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. - 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. - 7 p.m.
Phone: (843) 722-7550
Main Library
9 a.m. - 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. - 8 p.m.
Phone: (843) 805-6892
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Today's Hours
Baxter-Patrick James Island
9 a.m. - 8 p.m.
Phone: (843) 795-6679
West Ashley Library
9 a.m. - 7 p.m.
Phone: (843) 766-6635
Wando Mount Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 805-6888
Village Library
9 a.m. - 1 p.m.
Phone: (843) 884-9741
St. Paul's/Hollywood Library
9 a.m. - 8 p.m.
Phone: (843) 889-3300
Otranto Road Library
9 a.m. - 8 p.m.
Phone: (843) 572-4094
Mt. Pleasant Library
9 a.m. - 8 p.m.
Phone: (843) 849-6161
McClellanville Library
9 a.m. - 6 p.m.
Phone: (843) 887-3699
Keith Summey North Charleston Library
9 a.m. - 8 p.m.
Phone: (843) 744-2489
John's Island Library
9 a.m. - 8 p.m.
Phone: (843) 559-1945
Hurd/St. Andrews Library
9 a.m. - 8 p.m.
Phone: (843) 766-2546
Folly Beach Library
Closed
Phone: (843) 588-2001
Edisto Island Library
2 p.m. – 6 p.m.
Phone: (843) 869-2355
Dorchester Road Library
9 a.m. - 8 p.m.
Phone: (843) 552-6466
John L. Dart Library
9 a.m. - 7 p.m.
Phone: (843) 722-7550
Main Library
9 a.m. - 8 p.m.
Phone: (843) 805-6930
Bees Ferry West Ashley Library
9 a.m. - 8 p.m.
Phone: (843) 805-6892
Edgar Allan Poe/Sullivan's Island Library
Closed for renovations
Phone: (843) 883-3914
Mobile Library
9 a.m. - 5 p.m.
Phone: (843) 805-6909
Patron Login
menu
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Systemic hypereosinophilic syndromes: when autoimmunity is Th2 mediated.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Matucci A;Matucci A; Nencini F; Nencini F; Maggi E; Maggi E; Vultaggio A; Vultaggio A
- Source:Current opinion in allergy and clinical immunology [Curr Opin Allergy Clin Immunol] 2020 Apr; Vol. 20 (2), pp. 175-180.
- Publication Type:Journal Article; Review
- Language:English
- Additional Information
- Source: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 100936359 Publication Model: Print Cited Medium: Internet ISSN: 1473-6322 (Electronic) Linking ISSN: 14736322 NLM ISO Abbreviation: Curr Opin Allergy Clin Immunol Subsets: MEDLINE
- Publication Information: Original Publication: Hagerstown, Md. : Lippincott Williams & Wilkins, c2001-
- Subject Terms: Antibodies, Antineutrophil Cytoplasmic/*immunology ; Autoimmune Diseases/*immunology ; Hypereosinophilic Syndrome/*immunology ; Th2 Cells/*immunology; Autoimmune Diseases/blood ; Eosinophils/immunology ; Humans ; Hypereosinophilic Syndrome/blood ; Immunity, Innate ; Th1 Cells/immunology ; Th17 Cells/immunology
- Abstract: Purpose of Review: Clinical conditions associated with hypereosinophilia represent a field of particular interest, taking into account the epidemiological impact of the different primary and secondary forms. In addition to a classical Th1 response, also Th2 cells can be involved in the pathogenesis of autoimmune diseases, among them eosinophilic forms such as eosinophilic granulomatosis with polyangiitis.
Recent Findings: In patients with severe asthma, recent evidence highlights the role of pathogenic autoantibodies against autologous eosinophil proteins (e.g. eosinophil peroxidase) suggest the role of autoimmune mechanisms, particularly in patients in which asthma is included in eosinophilic vasculitis with antineutrophilic autoantibody positivity. Is now evident that in addition to Th2 cells, also type 2 innate lymphoid cells and Th1/Th17 cells play a central role in the pathogenesis of hypereosinophilic syndrome.
Summary: The definition of cellular and molecular mechanisms and the critical role of specific cytokines involved in the pathogenesis of hypereosinophilic syndrome open the way to new therapeutic strategies by using biological agents targeting these specific factors. - References: Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3:849–858.
Ravin KA, Loy M. The eosinophil in infection. Clin Rev Allergy Immunol 2016; 50:214–227.
Hellmark T, Ohlsson S, Pettersson A, et al. Eosinophils in antineutrophil cytoplasmic antibody associated vasculitis. BMC Rheumatol 2019; 3:9–21.
Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 2014; 10:474–483.
McBrian CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med (Lausanne) 2017; 4:93.
Ying S, Meng Q, Zeibecoglou K, et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1999; 163:6321–6329.
Carroll DJ, O'Sullivan JA, Nix DB, et al. Siglec-8 is an activating receptor mediating β2 integrin-dependent function in human eosinophils. J Allergy Clin Immunol 2018; 141:2196–2207.
Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019; 94:1149–1167.
Dispenza MC, Bocher BS. Diagnosis and novel approaches to the treatment of hypereosinophilc syndrome. Curr Hematol Malignancy Rep 2018; 13:191–201.
Greco A, Rizzo MI, De Virgilio A, et al. Churg-Strauss syndrome. Autoimmun Rev 2015; 14:341–348.
Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (former named Churg-Strauss syndrome). J Autoimmun 2014; 48-49:91–93.
Wu EY, Hernandez ML, Jannette JC, Falk RJ. Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. J Allergy clin Immunol Prac 2018; 6:1496–1504.
Lopez AF, Sanderson CJ, Gamble JR, et al. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167:219–224.
Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147–174.
Kiene M, Csernok E, Muller A, et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44:469–473.
Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology 2012; 51:1887–1893.
Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033–1039. Polzer K, Karonitsch T, Neumann T, et al. Eotaxin-3 is involved in Churg-Strauss syndrome---a serum marker closely correlating with disease activity. Rheumatology (Oxford). 2008;47(6):804--8.
Terrier B, Bieche I, Maisonobe T, et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 2010; 116:4523–4531.
Cosmi L, Liotta F, Maggi L, Annunziato F. Role of type 2 innate lymphoid cells in allergic diseases. Curr Allergy Asthma Rep 2017; 17:66.
Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol 2016; 137:75–86.e8.
Tsurikisawa N, Oshikata C, Watanabe M, et al. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. Clin Exp Allergy 2018; 48:1305–1316.
Saito H, Tsurikisawa N, Tsuburai T, et al. Cytokine production profile of CD4+ T cells from patients with active Churg-Strauss syndrome tends toward Th17. Int Arch Allergy Immunol 2009; 149 (Supp1):61–65.
Jakiela B, Sanak M, Szczeklik W, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2011; 29: (1 Suppl 64): S23–34.
Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, et al. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol 2013; 33:965–976.
Donma M, Karasu E, Ozdilek B, et al. CD4+, CD25+, FOXP3+ T regulatory cell levels in obese, asthmatic, asthmatic obese, and healthy children. Inflammation 2015; 38:1473–1478.
Eusebio M, Kuna P, Kraszula L, et al. The relative values of CD8+ CD25+ Foxp3brigh Treg cells correlate with selected lung function parameters in asthma. Int J Immunopathol Pharmacol 2015; 28:218–226.
Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999; 14:309–314.
Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008; 58:1839–1848.
Ueki S, Melo RC, Ghiran I, et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion competent eosinophil granules in humans. Blood 2013; 121:2074–2083.
Choi Y, Kim YM, Lee HR, et al. Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma. Allergy 2019; [Epub ahead of print].
Yousefi S, Simon D, Simon HU. Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol 2012; 24:736–739.
Choi Y, Le Pham D, Lee DH, et al. Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma. Exp Mol Med 2018; 50:104.
Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy 2013; 68:261–273.
Fujioka A, Yamamoto T, Takasu H, et al. The analysis of mRNA expression of cytokines from skin lesions in Churg–Strauss syndrome. J Dermatol 1998; 25:171–177.
Kiene M, Csernok E, Mueller A, et al. Elevated interleukin-4 and inter-leukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44:469–473.
Jakiela B, Sanak M, Szczeklik W, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg–Strauss syndrome. Clin Exp Rheumatol 2011; 29: (1 Suppl 64): S23–S34.
Mazzoni A, Maggi L, Liotta F, et al. Biological and clinical significance of T helper 17 cell plasticity. Immunology 2019; 158:287–295.
Nair P, Ochkur SI, Protheroe C, et al. Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy 2013; 68:1177–1184.
Mukherjee M, Bulir DC, Radford K, et al. Sputum autoantibodies in severe eosinophilic asthma. J Allergy Clin Immunol 2018; 141:1269–1279.
Gómez-Puerta JA, Bosch X. Antineutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol 2009; 175:1790–1798.
Mukherjee M, Thomas SR, Radford K, et al. Sputum antineutrophil cytoplasmic antibodies in serum antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med 2019; 199:158–170.
Wong CK, Dong J, Lam CW. Molecular mechanisms regulating the synergism between IL32 gamma and NOD for the activation of eosinophils. J Leukoc Biol 2014; 95:631–642.
Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med 2005; 143:632–638.
Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term follow-up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270–281.
Mukherjee M, Nair P. Autoimmune responses in severe asthma. Allergy Asthma Immunol Res 2018; 10:428–447.
Simon A, Subra JF, Guilpain P, et al. Detection of anti-pentraxin-3 autoantibodies in ANCA-associated vasculitis. PLoS One 2016; 11:e0147091.
Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term follow-up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270–281.
Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19–27.
Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26:545–553.
Hassani M, Koenderman L. Immunological and hematological effects of IL-5(Rα)-targeted therapy: an overview. Allergy 2018; 73:1979–1988.
Steinfeld J, Bradford ES, Brown J, et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019; 143:2170–2177.
Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017; 376:1921–1932.
Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma. (2019). Respir Med 2019; 1:.
Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016; 75:396–401.
Thiel J, Troilo A, Salzer U, et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 2017; 5:1556–1563. - Accession Number: 0 (Antibodies, Antineutrophil Cytoplasmic)
- Publication Date: Date Created: 20200128 Date Completed: 20210614 Latest Revision: 20210614
- Publication Date: 20240829
- Accession Number: 10.1097/ACI.0000000000000614
- Accession Number: 31985544
- Source:
Contact CCPL
Copyright 2022 Charleston County Public Library Powered By EBSCO Stacks 3.3.0 [350.3] | Staff Login
No Comments.